Barclays

Singapore-listed Frasers Centrepoint (FCL), which raised a £300m ($468.5m) five year loan from Barclays, BNP Paribas and Standard Chartered to fund the acquisition of boutique hotel chain Malmaison Hotel du Vin, has opened the loan into wider syndication.

Bond market participants were left pondering whether the sell-off in Brazilian assets had been exaggerated after a negative outlook from Standard & Poor’s triggered a rally and stabilisation in credit spreads in the country.

IBM and National Grid North America both took to the sterling market to sell tightly priced deals this week, showing there is arbitrage on offer for dollar funders — though both issuers kept their deals small.

Covered bond new issue premiums fell this week as six issuers raised a collective €5.5bn in three currencies with total demand of almost €8bn.

Canadian online poker platform Amaya has launched a $400m refinancing loan that will in part pay down debt incurred to acquire two rivals last year.

IBM dipped into the sterling market on Wednesday for a small but sharply priced seven year print. While some expected a larger deal size than £300m, they agreed that the deal was a positive sign for a market that has seen declining supply in 2015.

Barclays investment bank revenues held firm in the second quarter, helping the bank post a strong set of results that sent its share price up on Wednesday.

China concerns have failed to dissuade European corporate borrowers from going about their capital markets business this week, with a number of bonds in the works and acquisition loans progressing.

A series of German sub-sovereigns have printed deals in euros this week, adding to hopes that the market for the currency is slowly returning to strength after weeks of difficulty.

Ashtead, the UK-based equipment rental company, has increased a credit facility to $2.6bn to fund an expansion of its fleet.

This week could be the last opportunity for borrowers to bring euro deals before the market shuts down for summer, according to SSA bankers and issuers — and some trades are already on the production line.

Israeli pharmaceutical company Teva has 15 days to raise $33.75bn of funds to buy US firm Allergan's generics business.